Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25437665 | 0.97 | TP53 (0.32) | TP53TDP1 | |
| SCHEMBL6902693 | 0.82 | TP53 (0.46) | TP53TDP1 | |
| SCHEMBL9818290 | 0.79 | MAPK1 (0.33) | — | |
| SCHEMBL5983546 | 0.79 | ALDH1A1 (0.41) | — | |
| SCHEMBL4995915 | 0.78 | KDM4E (0.31) | TP53TDP1 | |
| SCHEMBL10567120 | 0.77 | — | — | |
| SCHEMBL2782186 | 0.77 | TP53 (0.39) | TP53TDP1 | |
| SCHEMBL8927345 | 0.76 | — | — | |
| SCHEMBL9818237 | 0.74 | SMN1; SMN2 (0.40) | TP53TDP1 | |
| SCHEMBL20543192 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006012425-A2 | PROCESSES FOR THE PRODUCTION OF AMINOALKYL GLUCOSAMINIDE PHOSPHATE AND DISACCHARIDE IMMUNOEFFECTORS, AND INTERMEDIATES THEREFOR | CORIXA CORPORATION (US) | 2006-02-02 | — | — | WO | claimed |
| US-20050107600-A1 | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor | CORIXA CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-05-19 | — | — | US | claimed |
| EP-1521762-A2 | PROCESSES FOR THE PRODUCTION OF AMINOALKYL GLUCOSAMINIDE PHOSPHATE AND DISACCHARIDE IMMUNOEFFECTORS, AND INTERMEDIATES THEREFOR | CORIXA CORPORATION (US) | 2005-04-13 | — | — | EP | claimed |
| US-20040267007-A1 | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors and intermediates therefor | CORIXA CORPORATION | 2004-12-30 | — | — | US | claimed |
| US-20040138182-A1 | Colchicine derivatives, process for preparing them, products obtained therefrom and use thereof | AVENTIS PHARMA S.A. (FR) | 2004-07-15 | — | — | US | claimed |
| WO-2004005308-A2 | PROCESSES FOR THE PRODUCTION OF AMINOALKYL GLUCOSAMINIDE PHOSPHATE AND DISACCHARIDE IMMUNOEFFECTORS, AND INTERMEDIATES THEREFOR | CORIXA CORPORATION (US) | 2004-01-15 | — | — | WO | claimed |
| US-4229203-A | INCREASED SUCROSE YIELD | W. R. GRACE & CO. (US) | 1980-10-21 | — | — | US | claimed |
| EP-4744667-A2 | EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF | The Queen's University Of Belfast (GB) | 2026-05-20 | — | — | EP | disclosed |
| US-12594292-B2 | Antiviral prodrugs, intermediate-and long-acting formulations and methods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-04-07 | — | — | US | disclosed |
| WO-2025151707-A1 | METHOD FOR PREPARING MULTIMERS OF PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | ENTRADA THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| US-20250177428-A1 | ANTIVIRAL PRODRUGS, INTERMEDIATE-AND LONG-ACTING FORMULATIONS AND METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-06-05 | — | — | US | disclosed |
| US-20250163093-A1 | EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2025-05-22 | — | — | US | disclosed |
| CN-110662542-B | Nicotinoyl nucleosides and reduced nicotinoyl nucleosides, modified derivatives thereof, phosphorylated analogs thereof, adenosine dinucleotide conjugates thereof, and efficient and scalable synthesis of novel crystalline forms thereof | 英国贝尔法斯特女王大学 | 2025-04-08 | — | — | CN | disclosed |
| EP-0272330-A1 | 1,1,2-TRIARYL-1-BUTENE DERIVATIVES | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1988-06-29 | — | — | EP | disclosed |
| US-4670424-A | Cyclic pyrophosphates of purine and pyrimidine acyclonucleosides | MERCK & CO., INC. (US) | 1987-06-02 | — | — | US | disclosed |
| EP-0138656-A1 | Cyclic pyrophosphates of purine and pyrimidine acyclonucleosides, their preparation and their application in anti-viral compositions | MERCK & CO. INC. (US) | 1985-04-24 | — | — | EP | disclosed |
| US-4469682-A | PARASITICIDES | MERCK & CO., INC. (US) | 1984-09-04 | — | — | US | disclosed |
| EP-0115930-A1 | Avermectin and milbemycin phosphate esters | MERCK & CO. INC. (US) | 1984-08-15 | — | — | EP | disclosed |
| US-4229203-A | INCREASED SUCROSE YIELD | W. R. GRACE & CO. (US) | 1980-10-21 | — | — | US | disclosed |
| US-4145540-A | ANTIBIOTICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1979-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163093-A1 | EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF | NAPRT, NAMPT, CD38 | TP53 3698/4885TDP1 629/4885 |
| US-12594292-B2 | Antiviral prodrugs, intermediate-and long-acting formulations and methods | ACE2, SARS1, FURIN | TP53 3086/4885TDP1 2997/4885 |
| US-20040267007-A1 | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors and intermediates therefor | DDOST, STT3A, STT3B | TP53 3230/4885TDP1 4410/4885 |
| US-20050107600-A1 | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor | DDOST, AGL, GALE | TP53 2990/4885TDP1 4340/4885 |
| US-20040138182-A1 | Colchicine derivatives, process for preparing them, products obtained therefrom and use thereof | WEE1, NOTUM, WEE2 | TP53 158/4885TDP1 98/4885 |
| US-20250177428-A1 | ANTIVIRAL PRODRUGS, INTERMEDIATE-AND LONG-ACTING FORMULATIONS AND METHODS | SARS1, ACE2, FURIN | TP53 2583/4885TDP1 2712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.